302 related articles for article (PubMed ID: 22814814)
1. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
Fritz JS; Blair C; Oudiz RJ; Dufton C; Olschewski H; Despain D; Gillies H; Kawut SM
Chest; 2013 Feb; 143(2):315-323. PubMed ID: 22814814
[TBL] [Abstract][Full Text] [Related]
2. Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials.
Chin KM; Bartolome S; Miller K; Blair C; Gillies H; Torres F
Int J Clin Pract; 2014 May; 68(5):568-77. PubMed ID: 24499136
[TBL] [Abstract][Full Text] [Related]
3. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
Safdar Z
Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
[TBL] [Abstract][Full Text] [Related]
4. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
[TBL] [Abstract][Full Text] [Related]
5. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
Frantz RP; McDevitt S; Walker S
J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
[TBL] [Abstract][Full Text] [Related]
6. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
8. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.
Farber HW; Miller DP; McGoon MD; Frost AE; Benton WW; Benza RL
J Heart Lung Transplant; 2015 Mar; 34(3):362-8. PubMed ID: 25312386
[TBL] [Abstract][Full Text] [Related]
9. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
[TBL] [Abstract][Full Text] [Related]
12. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
[TBL] [Abstract][Full Text] [Related]
13. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.
Frantz RP; Farber HW; Badesch DB; Elliott CG; Frost AE; McGoon MD; Zhao C; Mink DR; Selej M; Benza RL
Chest; 2018 Jul; 154(1):126-135. PubMed ID: 29355551
[TBL] [Abstract][Full Text] [Related]
14. The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis.
Mirsaeidi M; Omar HR; Baughman R; Machado R; Sweiss N
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):317-320. PubMed ID: 28079843
[TBL] [Abstract][Full Text] [Related]
15. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
[TBL] [Abstract][Full Text] [Related]
16. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.
Leuchte HH; Holzapfel M; Baumgartner RA; Neurohr C; Vogeser M; Behr J
Chest; 2005 Oct; 128(4):2368-74. PubMed ID: 16236896
[TBL] [Abstract][Full Text] [Related]
17. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan May Improve Exercise Tolerance and Cardiac Function in Patients With Pulmonary Hypertension.
Li XQ; Li YJ; Wang Y
Clin Ther; 2015 Jun; 37(6):1270-9. PubMed ID: 25862136
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
Blalock SE; Matulevicius S; Mitchell LC; Reimold S; Warner J; Peshock R; Torres F; Chin KM
J Card Fail; 2010 Feb; 16(2):121-7. PubMed ID: 20142023
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
